Hepatocellular carcinoma

伦瓦提尼 肝细胞癌 瑞戈非尼 催眠药 索拉非尼 卡波扎尼布 无容量 医学 脂肪性肝炎 彭布罗利珠单抗 癌症 肿瘤科 内科学 脂肪肝 免疫疗法 结直肠癌 疾病
作者
Josep Maria Llovet,Robin Kate Kelley,Augusto Villanueva,Amit G. Singal,Eli Pikarsky,Sasan Roayaie,Riccardo Antonio Lencioni,Kazuhiko Koike,Jessica Zucman‐Rossi,Richard S. Finn
出处
期刊:Nature Reviews Disease Primers [Nature Portfolio]
卷期号:7 (1): 6-6 被引量:7974
标识
DOI:10.1038/s41572-020-00240-3
摘要

Liver cancer remains a global health challenge, with an estimated incidence of >1 million cases by 2025. Hepatocellular carcinoma (HCC) is the most common form of liver cancer and accounts for ~90% of cases. Infection by hepatitis B virus and hepatitis C virus are the main risk factors for HCC development, although non-alcoholic steatohepatitis associated with metabolic syndrome or diabetes mellitus is becoming a more frequent risk factor in the West. Moreover, non-alcoholic steatohepatitis-associated HCC has a unique molecular pathogenesis. Approximately 25% of all HCCs present with potentially actionable mutations, which are yet to be translated into the clinical practice. Diagnosis based upon non-invasive criteria is currently challenged by the need for molecular information that requires tissue or liquid biopsies. The current major advancements have impacted the management of patients with advanced HCC. Six systemic therapies have been approved based on phase III trials (atezolizumab plus bevacizumab, sorafenib, lenvatinib, regorafenib, cabozantinib and ramucirumab) and three additional therapies have obtained accelerated FDA approval owing to evidence of efficacy. New trials are exploring combination therapies, including checkpoint inhibitors and tyrosine kinase inhibitors or anti-VEGF therapies, or even combinations of two immunotherapy regimens. The outcomes of these trials are expected to change the landscape of HCC management at all evolutionary stages. Hepatocellular carcinoma (HCC), the most common type of primary liver cancer, is one of the leading causes of cancer-related death in the world. This Primer summarizes the current knowledge on the epidemiology, pathogenetic mechanisms and diagnosis of HCC and provides an update on key advancements in the management of this disease.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
zi完成签到,获得积分20
刚刚
1秒前
1秒前
1秒前
所所的应助被大胆的自行车采纳,获得10
2秒前
3秒前
香蕉觅云的应助被mof采纳,获得10
4秒前
海绵宝宝完成签到 ,获得积分10
5秒前
5秒前
5秒前
初初初啊发布了新的文献求助10
5秒前
科研通AI2S的应助被科研通管家采纳,获得10
5秒前
DW的应助被科研通管家采纳,获得10
6秒前
深情安青的应助被科研通管家采纳,获得10
6秒前
科研通AI2S的应助被密苏里采纳,获得10
6秒前
6秒前
风吹麦浪的应助被科研通管家采纳,获得10
6秒前
Owen的应助被科研通管家采纳,获得10
6秒前
苏莱曼完成签到,获得积分10
6秒前
丘比特的应助被科研通管家采纳,获得10
6秒前
无花果的应助被科研通管家采纳,获得10
6秒前
Hello的应助被科研通管家采纳,获得10
6秒前
无极微光的应助被科研通管家采纳,获得20
7秒前
7秒前
雯雯少完成签到,获得积分10
7秒前
无花果的应助被科研通管家采纳,获得10
7秒前
无极微光的应助被科研通管家采纳,获得20
7秒前
7秒前
共享精神的应助被科研通管家采纳,获得10
7秒前
renn发布了新的文献求助20
7秒前
今后的应助被科研通管家采纳,获得10
7秒前
7秒前
CipherSage的应助被科研通管家采纳,获得10
7秒前
7秒前
Jun的应助被科研通管家采纳,获得10
8秒前
寒冷紫青的应助被清辉影采纳,获得80
8秒前
8秒前
Shu发布了新的文献求助10
9秒前
蟹lao板板完成签到,获得积分10
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183923
求助须知:如何正确求助?哪些是违规求助? 9573132
关于积分的说明 21829461
捐赠科研通 7781024
什么是DOI,文献DOI怎么找? 3434150
关于科研通互助平台的介绍 2558333
邀请新用户注册赠送积分活动 2480648